The CTC-chip: an Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients

Overview

Journal J Thorac Oncol

Publisher Elsevier

Specialties Oncology
Pulmonary Medicine

Date 2009 Feb 28

PMID 19247082

Citations 77

Authors

Lecia V Sequist

Sunitha Nagrath

Mehmet Toner

Daniel A Haber

Thomas J Lynch

Affiliations

Soon will be listed here.

Abstract

Circulating tumor cells (CTCs) are rare cells that originate from a malignancy and circulate freely in the peripheral blood. The ability to capture and study CTCs is an emerging field with implications for early detection, diagnosis, determining prognosis and monitoring of cancer, as well as for understanding the fundamental biology of the process of metastasis. Here, we review the development and initial clinical studies with a novel microfluidic platform for isolating these cells, the CTC-chip, and discuss its potential uses in the study of lung cancer.

Citing Articles

Development of PowerMag System II for Isolation of Circulating Tumor Cells with Improved Purity.

Ho C, Tsai H, Wang J, Wang C, Chiou C, Cheng J Biomedicines. 2025; 13(2).

PMID: 40002844 PMC: 11852382. DOI: 10.3390/biomedicines13020431.

How much do we know about the metastatic process?.

Rodriguez-Tirado C, Sosa M Clin Exp Metastasis. 2024; 41(4):275-299.

PMID: 38520475 PMC: 11374507. DOI: 10.1007/s10585-023-10248-0.

The Evolution of Affordable Technologies in Liquid Biopsy Diagnostics: The Key to Clinical Implementation.

Alexandrou G, Mantikas K, Allsopp R, Yapeter C, Jahin M, Melnick T Cancers (Basel). 2023; 15(22).

PMID: 38001698 PMC: 10670715. DOI: 10.3390/cancers15225434.

Liquid-based biomarkers in breast cancer: looking beyond the blood.

Shuai Y, Ma Z, Ju J, Wei T, Gao S, Kang Y J Transl Med. 2023; 21(1):809.

PMID: 37957623 PMC: 10644618. DOI: 10.1186/s12967-023-04660-z.

Development of a Microfluidic Device for Exosome Isolation in Point-of-Care Settings.

Ramnauth N, Neubarth E, Makler-Disatham A, Sher M, Soini S, Merk V Sensors (Basel). 2023; 23(19).

PMID: 37837121 PMC: 10574868. DOI: 10.3390/s23198292.

References

Allard W, Matera J, Miller M, Repollet M, Connelly M, Rao C . Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10(20):6897-904. DOI: 10.1158/1078-0432.CCR-04-0378. View

Nagrath S, Sequist L, Maheswaran S, Bell D, Irimia D, Ulkus L . Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007; 450(7173):1235-9. PMC: 3090667. DOI: 10.1038/nature06385. View

Sequist L, Lynch T . EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annu Rev Med. 2007; 59:429-42. DOI: 10.1146/annurev.med.59.090506.202405. View

Bean J, Brennan C, Shih J, Riely G, Viale A, Wang L . MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007; 104(52):20932-7. PMC: 2409244. DOI: 10.1073/pnas.0710370104. View

Bach P, Jett J, Pastorino U, Tockman M, Swensen S, Begg C . Computed tomography screening and lung cancer outcomes. JAMA. 2007; 297(9):953-61. DOI: 10.1001/jama.297.9.953. View

Sequist L, Bell D, Lynch T, Haber D . Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol. 2007; 25(5):587-95. DOI: 10.1200/JCO.2006.07.3585. View

Gupta G, Massague J . Cancer metastasis: building a framework. Cell. 2006; 127(4):679-95. DOI: 10.1016/j.cell.2006.11.001. View

Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

Asahina H, Yamazaki K, Kinoshita I, Sukoh N, Harada M, Yokouchi H . A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer. 2006; 95(8):998-1004. PMC: 2360715. DOI: 10.1038/sj.bjc.6603393. View

10.

Cristofanilli M, Hayes D, Budd G, Ellis M, Stopeck A, Reuben J . Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005; 23(7):1420-30. DOI: 10.1200/JCO.2005.08.140. View

11.

Kobayashi S, Boggon T, Dayaram T, Janne P, Kocher O, Meyerson M . EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352(8):786-92. DOI: 10.1056/NEJMoa044238. View

12.

Sequist L, Martins R, Spigel D, Grunberg S, Spira A, Janne P . First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008; 26(15):2442-9. DOI: 10.1200/JCO.2007.14.8494. View

13.

Paez J, Janne P, Lee J, Tracy S, Greulich H, Gabriel S . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-500. DOI: 10.1126/science.1099314. View

14.

Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N . Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol. 2006; 24(21):3340-6. DOI: 10.1200/JCO.2005.05.4692. View

15.

Hansen C, Quake S . Microfluidics in structural biology: smaller, faster em leader better. Curr Opin Struct Biol. 2003; 13(5):538-44. DOI: 10.1016/j.sbi.2003.09.010. View

16.

Engelman J, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park J . MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007; 316(5827):1039-43. DOI: 10.1126/science.1141478. View

17.

Maheswaran S, Sequist L, Nagrath S, Ulkus L, Brannigan B, Collura C . Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008; 359(4):366-77. PMC: 3551471. DOI: 10.1056/NEJMoa0800668. View

18.

Pao W, Miller V, Politi K, Riely G, Somwar R, Zakowski M . Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005; 2(3):e73. PMC: 549606. DOI: 10.1371/journal.pmed.0020073. View

19.

Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21):2129-39. DOI: 10.1056/NEJMoa040938. View